In the mid-late stage, the MAPK–MNK–eIF4E pathway was activated, and the STING–NF-κB pathway increased bone cancer pain via IL-1β, IL-6, and TNF-α (Barragán-Iglesias et al., 2020; Zhang et al., 2022). Here, IL6 is linked to bone cancer.